1. Home
  2. BSX vs GKOS Comparison

BSX vs GKOS Comparison

Compare BSX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Scientific Corporation

BSX

Boston Scientific Corporation

HOLD

Current Price

$98.57

Market Cap

149.7B

Sector

Health Care

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$107.89

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSX
GKOS
Founded
1979
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.7B
5.4B
IPO Year
1992
2015

Fundamental Metrics

Financial Performance
Metric
BSX
GKOS
Price
$98.57
$107.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
13
Target Price
$124.53
$122.08
AVG Volume (30 Days)
8.6M
1.1M
Earning Date
10-22-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
54.68
N/A
EPS
1.87
N/A
Revenue
$19,349,000,000.00
$469,820,000.00
Revenue This Year
$21.04
$30.89
Revenue Next Year
$11.45
$24.36
P/E Ratio
$52.71
N/A
Revenue Growth
21.61
30.38
52 Week Low
$85.98
$73.16
52 Week High
$109.50
$163.71

Technical Indicators

Market Signals
Indicator
BSX
GKOS
Relative Strength Index (RSI) 44.80 73.56
Support Level $100.50 $104.11
Resistance Level $101.91 $107.18
Average True Range (ATR) 2.12 4.40
MACD -0.13 1.26
Stochastic Oscillator 24.78 92.97

Price Performance

Historical Comparison
BSX
GKOS

About BSX Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: